原发性肝癌患者HBV感染血清学模式调查

目的 :研究HBV感染血清学模式与原发性肝癌的关系。方法 :分析 1996年 6月～ 2 0 0 0年 9月我院收治的 50 0例原发性肝癌患者的HBV感染血清学模式 ,与同期收治的 50 0例其他恶性肿瘤患者的HBV感染血清学模式进行比较。结果 :原发性肝癌患者HBV感染率为 89 6% ,显著高于其他恶性肿瘤患者。HBsAg和HBcAb同时阳性者占HBV感染肝癌的 79 9% ,占HBV感染其他恶性肿瘤的13 3% ,差异有极显著性 (P <0 0 1)。出现HBsAb者占原发性肝癌中HBV感染病例的 8 5% ,其他恶性肿瘤中HBV感染病例的 75 1% ,两者差异亦有极显著性 (P <0 0 1)。“大三阳”、“小三阳”和 (HBsAg HBcAb )者与肝癌相关的OR分别为 13 85、6 95和 14 69。结论 :HBsAg和HBcAb同时阳性的患者患肝癌的危险性最高 ;血清出现HBsAb的HBV感染者不易发展成肝癌

Serology of Hepatitis B Virus(HBV)Infection in Primary Liver Cancer

Objective To study the relation between the serological model of HBV infection and primary liver cancer(PLC).Methods Analysed the serological model of HBV infection in 500 primary liver cancer patients in our hospital from June 1996 to September 2000,and compared them with that of 500 cases of other malignant tumors in the same period.Results The rate of HBV infections in PLC was 89 6%,and only 43 4% in other cancers.In HBV infected patients, HBsAg and HBcAb both positive patients were 79 9% in PLC group,13 3% in other cancer group,but HBsAb positive patients were 75 1% in other cancer group,and 8 5% in PLC group,both significantly between two groups.Conclusions Patients with both HBsAg and HBcAb positive had the highest risk to be PLC;The presence of HBsAb in HBV infected patients could obviously inhibit the development of PLC.